Why the Pharmaceutical Research and Manufacturers of America doesn’t get it

ExpensiveRxJOHN J. CASTELLANI, the President and Chief Executive of PRMA just doesn’t get it.  In a letter to the NY Times in response to a story on the high cost of cancer drugs Mr Castellani used the argument that since 1980, life expectancy for cancer patients has increased by about three years, and about 80 percent of those gains are thanks to new treatments. Each new cancer medicine, whether it extends a life by months or years, helps build cumulative advances that drive medical discovery.  What Mr Castellani doesn’t understand is that cancer patients don’t just want to extend life they want cancer drugs that allow them to extend life with quality. Continue reading